Invivyd, Inc. (NASDAQ:IVVD) Sees Large Growth in Short Interest

by · The Cerbat Gem

Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 8,260,000 shares, an increase of 24.0% from the March 15th total of 6,660,000 shares. Based on an average daily volume of 14,600,000 shares, the short-interest ratio is presently 0.6 days. Currently, 10.9% of the shares of the stock are short sold.

Invivyd Stock Performance

Shares of NASDAQ:IVVD traded up $0.04 during trading on Friday, reaching $0.51. The stock had a trading volume of 1,533,471 shares, compared to its average volume of 4,284,218. The firm’s fifty day moving average is $0.87 and its 200 day moving average is $0.79. Invivyd has a 52 week low of $0.35 and a 52 week high of $2.74. The stock has a market cap of $61.18 million, a price-to-earnings ratio of -0.26 and a beta of 0.41.

Invivyd (NASDAQ:IVVD – Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.10. The business had revenue of $13.80 million for the quarter, compared to analyst estimates of $13.57 million. On average, research analysts forecast that Invivyd will post -1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IVVD. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a research note on Thursday, March 20th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a report on Wednesday, March 26th.

View Our Latest Stock Report on IVVD

Institutional Trading of Invivyd

Hedge funds have recently modified their holdings of the stock. Barclays PLC increased its stake in Invivyd by 7.8% in the fourth quarter. Barclays PLC now owns 127,180 shares of the company’s stock valued at $56,000 after purchasing an additional 9,207 shares in the last quarter. State Street Corp increased its position in Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after buying an additional 35,904 shares in the last quarter. Jane Street Group LLC raised its stake in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after buying an additional 87,358 shares during the period. Renaissance Technologies LLC bought a new position in Invivyd in the fourth quarter worth approximately $74,000. Finally, Two Sigma Investments LP increased its holdings in shares of Invivyd by 125.3% during the fourth quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock valued at $163,000 after acquiring an additional 204,188 shares in the last quarter. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

(Get Free Report)

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

Read More